Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
⁶⁸Ga-ABS011 is an investigational gallium-68-labeled positron emission tomography (PET) radiodiagnostic tracer designed to target human epidermal growth factor receptor 2 (HER2). It consists of a single-domain antibody (sdAb) conjugated to a NOTA chelator and radiolabeled with gallium-68. The tracer is designed to bind HER2 rapidly while unbound tracer clears quickly from the bloodstream, enabling same-day, whole-body PET imaging of HER2 expression across multiple lesions. This non-invasive approach helps reveal spatial heterogeneity in HER2 status that single-lesion biopsies may miss, thereby guiding patient selection and therapy monitoring in HER2-driven solid tumors, such as breast and gastric cancers. Originally developed by Abscint SA (a spin-off from Vrije Universiteit Brussel), the global rights to develop, manufacture, and commercialize the asset were acquired by Curium in 2026.
| Indication | Highest phase | Status |
|---|---|---|
| gastric cancer and precursor lesions | Preclinical | Active |
| metastatic breast cancer (mBC) | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: metastatic breast cancer (mBC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ⁶⁸Ga-ABS011.
Work on ⁶⁸Ga-ABS011? Claim this page to correct or add information. Claim this page